Akebia Therapeutics' stock is down 28% after a proposed stock offering, with declining Auryxia revenues and significant financial challenges. Vafseo's market launch shows some promise, but it's a ...

Akebia Therapeutics AKBA recently announced that it is floating a secondary issue of 25 million shares of its common stock to the public at an issue price of $2 per share, amounting to $50 million.The ...

Full-Year Revenue: $160.2 million in 2024, down from $194.6 million in 2023. Auryxia Net Product Revenue: $44.4 million in Q4 2024, down from $53.2 million in Q4 2023; $152.2 million in 2024 ...